Cello Health launches FutureScope
pharmafile | May 2, 2014 | News story | Medical Communications | cello health, futurescope, mdi
Cello Health that came to being in February following the combination of its Group agencies into one brand, has launched its first new offering.
Known as ‘FutureScope’, the firm’s new unit is designed to help healthcare businesses understand the likely future market dynamics and customer needs within a therapy area, so that they can identify and focus development on the most commercially relevant opportunities.
The process involves developing future scenarios based on scientific and clinical trends, economic and political drivers, and likely competitive entrants.
These scenarios are then used to characterise future market needs from the perspective of payers, patients, prescribers and providers. The ultimate goal is to identify future opportunities can be assessed and prioritised on their potential for commercial success.
“Commercial success for biopharmaceutical products entering today’s marketplace is increasingly difficult, and will be even more difficult in the future,” says Steve Mather, of Cello Health Consulting, the strategic consulting arm of Cello Health.
He goes on: “The healthcare landscape is changing at a rapid pace, the customer needs today will likely not be the same as they are in the future. That means that understanding likely future market dynamics and stakeholder needs is essential to ensuring commercial success – and FutureScope has been designed to achieve just that.
“Developing drugs and collecting the necessary data to meet payer needs is becoming essential in today’s constrained healthcare marketplace. FutureScope helps life science companies reduce some of the uncertainty around early product development and determine which opportunities are the most viable and most commercially attractive to pursue.
“FutureScope provides healthcare business with the confidence to make the best commercial decisions early in the development and commercialisation process.”
Although led from Cello Health’s strategic consulting arm, the teams that deliver FutureScope will be drawn from across the group’s three capabilities.
Ben Adams
Related Content
BASF and chemical giants building new MDI plant
BASF, Huntsman, Shanghai Hua Yi, Shanghai Chlor-Alkali and SINOPEC are teaming up to construct a …
New Alzheimer’s test ‘90% accurate’
US researchers have developed a blood test which they say is able to predict with …
